Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.
Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.
Methotrexate was granted FDA approval on 7 December 1953.
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 50
- Registration Number
- NCT00002665
- Locations
- 🇺🇸
CCOP - Dayton, Kettering, Ohio, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic Cancer Center, Cleveland, Ohio, United States
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
- Conditions
- Interventions
- Drug: CMF regimenBiological: filgrastimDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: mesnaDrug: epirubicin hydrochlorideDrug: fluorouracilProcedure: peripheral blood stem cell transplantationDrug: methotrexateDrug: tamoxifen citrateRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 344
- Registration Number
- NCT00002784
- Locations
- 🇦🇺
Queen Elizabeth Hospital, Adelaide, South Australia, Australia
🇦🇺Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00002831
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Tamoxifen in Treating Women With High-Risk Breast Cancer
- Conditions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 672
- Registration Number
- NCT00002542
- Locations
- 🇨🇦
Credit Valley Hospital, Mississauga, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Canada
🇨🇦Stronach Regional Health Centre at Southlake, Newmarket, Canada
Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 242
- Registration Number
- NCT00002618
- Locations
- 🇺🇸
San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States
🇺🇸Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States
🇨🇭Clinique de Pediatrie, Geneva, Switzerland
Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00002557
- Locations
- 🇿🇦
University of Cape Town School of Medicine, Cape Town, South Africa
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002691
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: leucovorin calciumDrug: liposomal cytarabineDrug: mercaptopurineDrug: mesnaDrug: methotrexateDrug: therapeutic hydrocortisoneDrug: thiotepaDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT00002704
- Locations
- 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- First Posted Date
- 2004-06-28
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005854
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
- Conditions
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 80
- Registration Number
- NCT00003549
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.